Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Related Posts
Yale classmates warn Trump Treasury Secretary Bessent he risks enabling descent ‘into fascism’
A new letter to Scott Bessent accuses President Donald Trump of usurping the authority of Congress and U.S. courts since regaining the White House.
Nvidia CEO Jensen Huang hammers chip controls that ‘effectively closed’ China market
On his company’s earnings call, Jensen Huang said that China would “move on” with or without Nvidia’s chips.
Amazon’s advertising business grew 19% in the third quarter
Amazon’s online advertising business jumped 19% year over year to $14.3 billion in the third quarter.